electroCore, a leading bioelectronic medicine company, have received a revised Medical Device License (MDL) from Health Canada to extend its labelling of electroCore’s gammaCore nVNS to include the acute and preventive treatment of migraine in adolescents (aged 12 – 17 years old), giving electroCore regulatory approval in Canada for gammaCore. Now approved for a wide range of headache treatments in adolescents and adults, it also can be used to treat cluster headaches in adults. The label extension was based on randomized controlled trials of gammaCore for the acute and preventive treatment of migraines.
Read more here
More on: Health News Regulatory